What Happened?
Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 3.1% in the afternoon session after continued positive momentum as the company reported stronger-than-expected second-quarter results and raised its full-year 2025 revenue and earnings guidance.
The fertility benefits leader reported stronger-than-expected second-quarter results and raised its outlook for 2025. Progyny posted adjusted Q2 earnings of $0.48 per share, beating analyst estimates, on revenue of $332.9 million. Following the strong performance, the company boosted its full-year guidance, now projecting revenue of around $1.25 billion at the midpoint, up from its previous forecast of $1.21 billion. Management also raised its full-year adjusted earnings guidance to approximately $1.74 per share at the midpoint. This updated forecast highlights robust underlying growth driven by expanding demand for its fertility and family building benefits.
After the initial pop the shares cooled down to $24.15, up 3.1% from previous close.
Is now the time to buy Progyny? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Progyny’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 5 days ago when the stock gained 5.1% on the news that markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
Progyny is up 36.2% since the beginning of the year, and at $24.15 per share, it is trading close to its 52-week high of $24.82 from September 2024. Investors who bought $1,000 worth of Progyny’s shares 5 years ago would now be looking at an investment worth $824.65.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.